Title:Upcoming Drifts in Bio-similars
Volume: 16
Issue: 1
Author(s): Geeta Aggarwal, Manju Nagpal*, Ameya Sharma, Vivek Puri and Gitika Arora Dhingra
Affiliation:
- Chitkara College of Pharmacy, Chitkara University, Punjab,India
Keywords:
Biologics, biosimilars, regulatory, EMA, FDA, global market.
Abstract:
Background: Biopharmaceuticals such as biological, medicinal products have been in
clinical use over the past three decades and have benefited the therapy of degenerative and critical
metabolic diseases. It is forecasted that the market of biologics will be going to increase at a rate of
˃ 20% per year, and by 2025, more than 50% of new drug approvals might be biological products.
The increasing utilization of the biologics necessitates cost control, especially for innovator products
that have a lengthy period of exclusive usage. As the first wave of biopharmaceuticals is expired
or set to expire, it has led to various opportunities for the expansion of bio-similars i.e. copied
versions of original biologics with same the biological activity. Development of biosimilars is expected
to promote market competition, meet worldwide demand, sustain the healthcare systems and
maintain the incentives for innovation.
Methods: Appraisal of published articles from peer-reviewed journals, PubMed literature, latest
news and guidelines from European Medicine Agency, US Food Drug Administration (FDA) and
India were used to identify data for review.
Results: Main insights into the quality requirements concerning biologics, the current status of
regulation of bio-similars and upcoming challenges lying for the upgrading of the marketing
authorization of biosimilars have been incorporated. Compiled literature on the therapeutic status,
regulatory guidelines and the emerging trends and opportunities of biosimilars has been thoroughly
stated.
Conclusion: Updates on biosimilars will support to investigate the possible impact of bio-similars
on the healthcare market.
